Endometrioid carcinoma arising from the remnant ovarian tissue
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20242838Keywords:
Chemotherapy, Endometrioid carcinoma, Molecular studiesAbstract
Endometrioid carcinoma of ovary is a subtype of epithelial tumours of the ovary. It can be distinguished from serous and mucinous tumours by presence of tubular glands resembling that of malignant endometrium. Traditionally, Ovarian carcinoma treatment involves the combination of cytoreductive surgery and platinum-based chemotherapy. Fortunately, because of a better overall understanding of ovarian tumorigenesis and advancements in the disease’s epigenetic and molecular profiling, a paradigm shift has emerged with the identification of new disease biomarkers and the proposal of targeted therapeutic approaches to postpone disease recurrence and decrease side effects, while increasing patients’ survival. It is usually associated with poor prognosis due to late clinical presentation allied with the common acquisition of chemo resistance and a high rate of tumour recurrence. The chemotherapy backbone for patients with high-grade advanced epithelial ovarian cancer (HG-AOC) is carboplatin and paclitaxel followed by a maintenance therapy either with bevacizumab, with a PARP inhibitor, or with a combination of both, which is defined by the presence of a Homologous Recombination Deficiency (HRD) and by the BRCA1/2 status (This case showed a negative HRD and BRCA1/BRCA2 mutation status). Hence effective screening, accurate diagnosis and personalised multidisciplinary treatments are crucial for improving patient’s survival and quality of life. We report a case of endometrioid carcinoma of ovary arising from the remnant ovarian tissue in a 53year old women who underwent TAH+BSO done 12 years back for a benign cause and aims to summarize molecular studies involved in endometroid ovarian carcinoma pathogenesis as potential therapeutic targets.
Metrics
References
Choi JI, Park SB, Han BH, Kim YH, Lee YH, Park HJ, Lee ES. Imaging features of complex solid and multicystic ovarian lesions: proposed algorithm for differential diagnosis. Clinical Imaging. 2016;40(1):46-56.
Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN, Howe HL. Pathology and classification of ovarian tumours. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2003;97(10):2631-42.
Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran pathologic basis of disease, professional edition e-book. Elsevier health sciences; 2014. Available at: https://shop.elsevier.com/books/robbin.
Young R. WHO classification of tumours of female reproductive organs. Monodermal teratomas and somatic-type tumours arising from a dermoid cyst. 2014:63-5.
Hunn J, Rodriguez GC. Ovarian cancer:etiology, risk factors, and epidemiology. Clinical obstetrics and gynecology. 2012;55(1):3-23.
Czernobilsky B, Silverman BB, Mikuta JJ. Endometrioid carcinoma of the ovary. A clinicopathologic study of 75 cases. Cancer. 1970;26(5):1141-52.
Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG. Epithelial ovarian cancer risk: A review of the current genetic landscape. Clinical genetics. 2020;97(1):54-63.
Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. International journal of women's health. 2019:8;287-99.
Singla A. Epidemiology and risk factors for ovarian cancer. Preventive Oncology for the Gynecologist. 2019:223-31.
Mustafin C, Vesnin S, Turnbull A, Dixon M, Goltsov A, Goryanin I. Diagnostics of Ovarian Tumors in Postmenopausal Patients. Diagnostics. 2022;12(11):2619.
Weir CB. StatPearls Publishing. Treasure Island, FL, USA: 2022. BMI classification percentile and cut off points. 2021. Available at: https://www.ncbi.nlm.nih.
Kemppainen J, Hynninen J, Virtanen J, Seppänen M. PET/CT for evaluation of ovarian cancer. In Seminars in nuclear medicine. WB Saunders. 2019;49(6):484-92.
Opławski M, Średnicka A, Niewiadomska E, Boroń D, Januszyk P, Grabarek BO. Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy. Frontiers in Oncology. 2022;12:954008.
Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, et al. Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology. 2020;31(9):1240-50.
Wilczyński J, Paradowska E, Wilczyński M. Personalization of therapy in high-grade serous tubo-ovarian cancer—the possibility or the necessity. J Pers Med. 2023;14(1):49.
Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. InSeminars in oncology nursing WB Saunders. 2019;35(2):151-6.
McMullen M, Madariaga A, Lheureux S. New approaches for targeting platinum-resistant ovarian cancer. In Seminars in cancer biology. 2021;77:167-81.
Heitz F, Ataseven B, Staniczok C, Denkert C, Rhiem K, Hahnen E, et al. Implementing HRD testing in routine clinical practice on patients with primary high-grade advanced ovarian cancer. Cancers. 2023;15(3):818.
Kim S, Han Y, Kim SI, Kim HS, Kim SJ, Song YS. Tumor evolution and chemoresistance in ovarian cancer. NPJ precision oncology. 2018;2(1):20.
Foley OW, Rauh-Hain JA, Del Carmen MG. Recurrent epithelial ovarian cancer: an update on treatment. Oncology. 2013;27(4):288.
Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer chemotherapy and pharmacology. 2018;81:17-38.
Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis Jr JL. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9(3):389-93.
Van Driel WJ, Koole SN, Sikorska K, Schagen JH, Schreuder HW, Hermans RH, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. England J Med. 2018;378(3):230-40.
Issels RD. Hyperthermia adds to chemotherapy. European journal of cancer. 2008;44(17):2546-54.
Akter S, Rahman MA, Hasan MN, Akhter H, Noor P, Islam R, et al. Recent advances in ovarian cancer: therapeutic strategies, potential biomarkers, and technological improvements. Cells. 2022;11(4):650.
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. England J Med. 2011;365(26):2473-83.
Langdon SP, Herrington CS, Hollis RL, Gourley C. Estrogen signalling and its potential as a target for therapy in ovarian cancer. Cancers. 2020;12(6):1647.
Park SH, Cheung LW, Wong AS, Leung PC. Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor α. Molecular endocrinology. 2008;22(9):2085-98.
Lazennec G. Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer letters. 2006;231(2):151-7.
Iavazzo C, Gkegkes I. Regarding “Hormone Replacement Therapy Prescription after Premature Surgical Menopause”. J Mini Inv Gyn. 2020;27(6):1425.
Ledermann JA, Canevari S, Thigpen T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Onco. 2015;26(10):2034-43.
Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer and Metastasis Reviews. 2015;34:41-52.
Kurosaki A, Hasegawa K, Kato T, Abe K, Hanaoka T, Miyara A, et al. Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression. Int J Cancer. 2016;138(8):1994-2002.
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio is associated with favourable prognosis in ovarian cancer. Proc Nation Acad Sci. 2005;102(51):18538-43.
Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nature reviews Drug discovery. 2004;3(8):673-83.
Skorda A, Bay ML, Hautaniemi S, Lahtinen A, Kallunki T. Kinase inhibitors in the treatment of ovarian cancer: current state and future promises. Cancers. 2022;14(24):6257.
Liz-Pimenta J, Tavares V, Neto BV, Santos JM, Guedes CB, Araújo A, et al. Thrombosis and cachexia in cancer: two partners in crime? Cri t Rev Oncol/Hematol. 2023 Jun 1;186:103989.
Swier N, Versteeg HH. Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression. Thrombosis research. 2017;150:8-18.
Downloads
Published
How to Cite
Issue
Section
